Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate<i>R</i>‐[¹¹C]verapamil

Abstract

Even though we failed to detect statistically significant differences in R-[(11)C]verapamil model parameters between epileptogenic and nonepileptogenic brain regions, it cannot be excluded from our pilot data in a small sample size of patients that regionally enhanced P-gp activity might contribute to drug resistance in some patients with temporal lobe epilepsy.